AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06618573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid/Pyridoxine
Description: Treatment group received isoniazid 300mg and pyridoxine 10mg/day
Study NCT06618573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharum Lactis
Description: Control group received placebo
Study NCT06622577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cysteine
Description: Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
Study NCT06619665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: MK-6552 gelatin coated capsules taken orally two times 8 hours apart
Study NCT06619665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552 placebo
Description: MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Study NCT06619665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil tablet taken once orally
Study NCT06619665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil placebo
Description: Modafinil placebo tablet taken once orally
Study NCT06622863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene instructions will be given verbally by the periodontics resident
Description: Standard oral hygiene instructions will be given verbally by the periodontics resident
Study NCT06622863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
Description: Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
Study NCT06619431 — intervention group
Intervention type: DEVICE
Intervention: Mobile Application
Description: Rumbo is an easily shared bi-lingual application that helps Hispanic individuals with unhealthy substance use find and access treatment services and related resources. The application stands out from other eHealth tools by leveraging the collective efficacy of the Hispanic community to overcome barriers and support individuals' self-efficacy for engaging the treatment system. Rumbo's simple, user-centered design provides less-acculturated Hispanic individuals with a culturally appropriate tool to understand their needs within the complex US treatment system. Rumbo is comprised of four innovations: (1) a sharing function that facilitates its own implementation among the target population; (2) culturally responsive content and design; (3) problem identification and treatment navigation enhanced to include related resources; (4) an API that is designed for interoperability across extant technologies.
Study NCT06617988 — intervention group
Intervention type: OTHER
Intervention: Not applicable- observational study
Description: Not applicable- observational study
Study NCT06618183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat drug screen
Description: Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
Study NCT06618183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat laboratory analysis
Description: Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
Study NCT06620367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional guided bone regeneration
Description: 10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) covered with bilayer collagen membrane stabilized by tacks
Study NCT06620367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: digital guided bone regeneration
Description: 10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) placed by digital designed guide covered with bilayer collagen membrane stabilized by tacks
Study NCT06629584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
Study NCT06054243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
Study NCT06054243 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-A
Description: The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
Study NCT05176548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone-cardiac scintigraphy
Description: Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
Study NCT06349122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
Study NCT06349122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole, Vaginal
Description: In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
Study NCT05288296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic taping
Description: 1. The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~2. By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it.
Study NCT03081806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
Study NCT03081806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: X0002
Description: Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
Study NCT06010420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insoles
Description: Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
Study NCT05356975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Superset
Description: A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~1. One leg squat, side plank, and push up.~2. Deadlift, lumbar extension stretch, and row.~3. Glute bridge, crunches, and front raise.
Study NCT05356975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent
Description: Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
Study NCT06526078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Sessions of cognitive training exercises (15-20min each) self-administered via a web app
Study NCT06526078 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Sessions of sham training exercises (15-20min each) self-administered via a web app
Study NCT04888845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Plan
Description: The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
Study NCT04888845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis Response Plan
Description: Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
Study NCT04888845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured interview
Description: In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
Study NCT04888845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Assessment
Description: In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis.
Study NCT06237413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG2001 Tosilate Tablets
Description: ZG2001 will be administered orally once or twice daily in a continuous regimen
Study NCT06454422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wu qinxi
Description: Wuqinxi, also known as the Hundred-step Sweating Exercise, is one of the most emblematic Health qigong exercises. Huatuo, guided by the principle, formulated the 'Wuqinxi':  Running water is never stale and a door-hinge is never gets worm-eaten, and sums up the experiences of the fitness activities of Huatuo's predecessors that imitate the movements of tigers, deer, bears, apes, birds, and other animals, and are associated with human organs, meridians, and 'qi'
Study NCT06255379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuquinitinib+Tegafur Gimeracil Oteracil
Description: Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） >1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
Study NCT05520021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
Study NCT05520021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
Study NCT05896683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.
Study NCT06288269 — intervention group
Intervention type: OTHER
Intervention: Severity of Stroke and 1 year survival
Description: Evaluated from NIHSS and clinical outcome 1 year survival death
Study NCT05631106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Resistance Training
Description: During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
Study NCT05631106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching, Balance, and Range of motion
Description: The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
Study NCT06230666 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT06230666 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT06349122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will not be screened using molecular biology techniques in this group. The management of these patients is a matter of routine for health professionals. They will be free to prescribe a standard vaginal swab if symptoms are present and to treat their patients according to their usual protocols. No routine sampling is recommended in the absence of a history
Study NCT04676711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312
Description: Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Study NCT04676711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Study NCT05192408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Description: Individual intervention will comprise:~1. Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~2. Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~3. Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone.
Study NCT05192408 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patient Education Materials
Study NCT04576065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WFIT
Description: access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
Study NCT04888715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWN12088
Description: Prolyl-tRNA synthetase (PRS) inhibitor
Study NCT04888715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone
Study NCT04888715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib
Study NCT06266156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Score of anxiety questionnaire
Description: All participants were answered the dental anxiety questionnaire.
Study NCT06266156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate
Description: All participants heart rate were measured with finger type pulse oxymeter.
Study NCT06266156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oxygen saturation
Description: All participants oxygen saturation were measured with finger type pulse oxymeter.
Study NCT05137340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure and Non-invasive positive pressure ventilation
Description: After transfer to NICU ward, infants were randomly assigned to NCPAP group and NIPPV group. Patients diagnosed with NRDS on non-invasive respiratory support (NIPPV or NCPAP) were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth.
Study NCT05137340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal continuous positive airway pressure and Non-invasive positive pressure ventilation
Description: After transfer to NICU ward, infants were randomly assigned to NCPAP group and NIPPV group. Patients diagnosed with NRDS on non-invasive respiratory support (NIPPV or NCPAP) were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth.
Study NCT05236894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking
Description: Smoke preferred brand of cigarette
Study NCT05236894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given lower dose nicotine pouch
Study NCT05236894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given higher dose nicotine pouch
Study NCT05236894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05236894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05236894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given 3mg nicotine pouch (Aim 2)
Study NCT04794205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Beta-Caryophyllene
Description: 5 mg BCP
Study NCT04794205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose Beta-Caryophyllene
Description: 30 mg BCP
Study NCT04794205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Beta-Caryophyllene
Description: 150 mg BCP
Study NCT04794205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug.
Study NCT04829331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restrata
Description: Restrata is a sterile, single use device intended for use in local management of wounds
Study NCT04701918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous injection through a vein (IV) every 3 weeks
Study NCT04701918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Needle inserted through the skin and into the tumor using CT guidance
Study NCT04701918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Intravenous injection through a vein (IV) every 2 weeks
Study NCT04911335 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Faringel plus and oral hygiene
Description: The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
Study NCT05950581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Twin-Block Appliance with Clear Plates.
Description: Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
Study NCT05950581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional Twin-Block appliance
Description: Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
Study NCT05109871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KForce Link
Description: Traction (pull-type) dynamometer
Study NCT05330273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
Study NCT05330273 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
Study NCT05330273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
Study NCT04734847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Non-invasive magnetic stimulation of the brain
Study NCT06408311 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ENC-201-CED hPI
Description: macro-encapsulated human primary islets
Study NCT04844905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.